Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01910506 · ClinicalTrials.gov registry record · Phase 1
RDEA3170 AME Study
A Phase 1 study, sponsored by Ardea Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT01910506 is a Phase 1 study that has completed, run by Ardea Biosciences. The registered enrollment target is 8 participants.
The verdict
NCT01910506, a Phase 1 study, has completed, sponsored by Ardea Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study will determine the characteristics of absorption, metabolism, and excretion (AME) of RDEA3170 following a single 10 mg dose of RDEA3170 oral solution with 500 microcuries (µCi) of \[14 C\]RDEA3170 in healthy adult male subjects.
Interventions
- DRUG RDEA3170 10 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-08 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01910506
The ClinicalTrials.gov registry entry for NCT01910506 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ardea Biosciences, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RDEA3170 10 mg is the first listed.
NCT01910506 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01910506 about?
NCT01910506 is a clinical study titled "RDEA3170 AME Study". This study will determine the characteristics of absorption, metabolism, and excretion (AME) of RDEA3170 following a single 10 mg dose of RDEA3170 oral solution with 500 microcuries (µCi) of \[14 C\]RDEA3170 in healthy adult male subjects.
What is the current status of trial NCT01910506?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2013-08. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01910506?
The interventions under investigation include: RDEA3170 10 mg (DRUG).
Who is sponsoring clinical trial NCT01910506?
This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.